ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie raised its 2026 revenue guidance to $67.8 billion for the third time this year, driven by strong performance from Skyrizi and Rinvoq, which are offsetting Humira's patent-driven decline. The company's neuroscience portfolio, including Vyalev and migraine drugs, is also contributing to growth. However, aesthetics sales remain soft and oncology growth is subdued. AbbVie maintains a Zacks Rank #3 (Hold) rating with solid long-term prospects.